BMS 986012

Drug Profile

BMS 986012

Alternative Names: Anti-fucosyl-GM1 - Bristol-Myers Squibb; BMS986012

Latest Information Update: 20 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fucosyl GM1 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer

Most Recent Events

  • 31 Oct 2016 Bristol-Myers Squibb plans a phase I trial for Small cell lung cancer in Japan (IV) (NCT02949895)
  • 07 Oct 2016 Preliminary efficacy, pharmacokinetic and adverse events data from a phase I/II trial in Small cell lung cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Oct 2016 Phase-I/II clinical trials in Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Spain (IV) (NCT02815592) after October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top